The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisinkexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (> _1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. 
Introduction
Lowering of low-density lipoprotein cholesterol (LDL-C) with statins by 1 mmol/L (39 mg/L) is associated with an approximate 20% reduction in the rate of myocardial infarction (MI). 1 The proprotein convertase subtilisin-kexin Type 9 (PCSK9) inhibitors evolocumab and alirocumab reduce LDL-C by >1 mmol/L below statin-treated levels and further reduce the risk of MI among patients treated with statins. 2, 3 In 2007, the Universal Definition of MI Task Force introduced a classification of five types of MI based on presumptive mechanisms, including Type 1 due to spontaneous plaque rupture or fissuring with thrombus, Type 2 due to myocardial supply and/or demand imbalance, Type 3 with cardiac death suggestive of MI without biomarker elevation, Type 4 related to percutaneous coronary intervention (PCI), and Type 5 related to coronary artery bypass grafting (CABG). 4 In the FOURIER trial, 5 which randomized stable patients with a history of MI, stroke, or peripheral vascular disease, evolocumab reduced the number of MIs vs. placebo. Evolocumab reduced the number of Type 1 and Type 4 MIs, but not Type 2 MIs. In this pre-specified analysis from the ODYSSEY OUTCOMES trial, we studied the occurrence and outcomes of the different types of MIs in patients with recent acute coronary syndrome (ACS) and elevated LDL-C despite intensive statin therapy who were randomized to receive alirocumab or placebo and followed for cardiovascular outcomes.
Methods
The study design 6 and primary results 3 have been published. Qualifying patients were > _40 years, provided written informed consent, had been hospitalized with ACS (acute MI or unstable angina) 1-12 months before randomization, and had an LDL-C level > _1.81 mmol/L (70 mg/dL), nonhigh-density lipoprotein cholesterol (non-HDL-C) > _2.59 mmol/L (100 mg/dL), or apolipoprotein B > _2.07 mmol/L (80 mg/dL), measured after > _2 weeks of stable treatment with atorvastatin 40-80 mg daily, rosuvastatin 20-40 mg daily, or the maximum-tolerated dose of either statin (including no statin in case of documented intolerance). Randomization (1:1) to treatment with alirocumab 75 mg or matching placebo, stratified by country, was performed, with 18 924 patients meeting the entry criteria. Study medication was given by subcutaneous injection every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL-C level of 0.6-1.3 mmol/L (details on the dosing strategy are provided in Supplementary material online, Text S1). The primary composite endpoint was death due to coronary heart disease, non-fatal MI, fatal and non-fatal ischaemic stroke, or unstable angina requiring hospitalization. The incidence of MI was defined as the time to first occurrence of MI. In a pre-specified analysis, the types of MI were defined according to the Third Universal Definition 7 and were adjudicated by a central clinical events committee blinded to the treatment assignment and lipid levels. Biomarker measurements were not mandated after PCI or CABG. 9 The effects of treatment assignment on death before or after a Type 1 or Type 2 MI were determined in separate Cox regression models for each MI type by interactions between incident MI as a time-varying covariate and treatment, with stratification by geographical region. For a given patient, an MI that occurred on the same day as death was excluded from the analysis. Sensitivity analyses of time to MI included events on the same day as death. All analyses were conducted according to intention-to-treat, including all patients and events from randomization to common study end date (11 November 2017) . Unless otherwise indicated, analyses were prespecified before unblinding of the study database. Analyses were performed in SAS 9.4 and S þ 8.2.
Results
A total of 18 924 patients were randomized at 1315 sites in 57 countries, with 9462 patients assigned to alirocumab and 9462 patients to placebo. Median follow-up was 2. obstructive pulmonary disease, peripheral artery disease, or malignant disease, and were less likely to be smokers. Baseline LDL-C, lipoprotein(a), and high-sensitivity C-reactive protein levels were higher in patients with than without MI. Baseline LDL-C, lipoprotein(a), and high-sensitivity C-reactive protein did not differ between those with Type 1 or Type 2 MI. Triglyceride levels were higher at baseline in patients who had MIs compared with those not having MIs, and patients with Type 2 MIs had lower triglyceride levels than patients with Type 1 MIs (P = 0.012).
Mean LDL-C levels were reduced by 54% with alirocumab vs. placebo, from 2.39 mmol/L (92 mg/dL) to 1.24 mmol/L (48 mg/dL), at 12 months. Alirocumab reduced the occurrence of postrandomization MI vs. placebo [6.8% vs. 7.9%; hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77-0.95; P = 0.003]. Both Type 1 MIs (P = 0.032) and Type 2 MIs (P = 0.025) were reduced with alirocumab ( Table 2 ). There was no apparent effect on Type 3, 4, or 5 MIs.
Take home figure shows the Kaplan-Meier curve of the occurrence of Type 1 and Type 2 MIs after randomization by treatment group. A benefit of alirocumab treatment on Type 1 MI was apparent after year 1 and increased after year 2, whereas the treatment effect on Type 2 MI appeared more constant over time (Figure 1 ). These observations are supported by post hoc model results: allowing the treatment HR to change for each of the time intervals indicated in Figure 1 fit the data better than a constant HR for Type 1 MI (P = 0.05) but not for Type 2 MI (P = 0.34).
Most MIs (82.7%) were non-ST-segment elevation MI (non-STEMI) and were significantly reduced with alirocumab (HR 0.82, 95% CI 0.72-0.93; P = 0.002). There were consistent effects on STEMIs. Q-wave MIs were identified in a minority (10.5%) of patients with interpretable electrocardiograms (ECGs), with consistent effects of alirocumab for Q-wave and non-Q-wave MIs ( Table 2) .
A sensitivity analysis including patients who died on the day of MI (n = 7 alirocumab; n = 11 placebo) showed similar effects of alirocumab on reducing both Type 1 and Type 2 MIs (Supplementary material online, Table S6 ).
Supplementary material online, Table S7 shows the effect of alirocumab on biomarker levels, predominantly cardiac troponin (92%) and high-sensitivity troponins (29%), at various cut-points. Alirocumab treatment was associated with no apparent reduction in smaller MIs (with peak biomarker levels <3 times the upper limit of normal) but with large reductions in larger MIs as defined by peak biomarker value. Tables 3 and 4 and Supplementary material online, Figure S1 show the independent predictors for Type 1 and Type 2 MIs, respectively. Most of the factors predicting occurrence of Type 1 or Type 2 MI were similar. Of note, baseline LDL-C was an independent predictor of occurrence of Type 1 but not Type 2 MI. Similarly, previous CABG, revascularization at the time of the index ACS event, current smoking, and previous stroke were significant predictors of occurrence of subsequent Type 1 MI but not Type 2 MI. Conversely, age (by discrete categories), history of chronic obstructive pulmonary disease, and lower baseline HDL-C levels were significant predictors of Type 2 but not Type 1 MI. Race, history of diabetes, hypertension, and peripheral artery disease were risk factors for both types of MI. Randomization to alirocumab was associated with lower risk of both types of MI. 
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Discussion
After an index ACS, there is a substantial incidence of recurrent MI.
In the placebo group of the ODYSSEY OUTCOMES trial, this incidence was 7.9% over a median follow-up of 2.8 years, despite high-intensity statin treatment and high use of other evidence-based therapies. The rate of Type 1 MI was more than double that of all other types combined. Alirocumab treatment reduced the overall incidence of MI, an observation that appears driven by a reduction in both Type 1 and Type 2 MIs. The treatment benefit on Type 1 MI increased with time elapsed since randomization, suggesting that treatment benefit may increase with longer treatment duration. The finding that a lipid-lowering treatment could reduce the incidence of Type 2 MI is novel. The benefit of alirocumab on reducing both types of MI was more pronounced when biomarker elevation, as a measure of infarct size, exceeded three times the upper limit of normal. It is unlikely that the reduced occurrence of Type 2 MI with alirocumab treatment resulted from an effect on myocardial oxygen demand. However, alirocumab treatment may have improved myocardial oxygen supply. In the GLAGOV trial, 10 evolocumab treatment added to statin treatment in patients with coronary artery disease (CAD) produced substantial further lowering of LDL-C and reduced the volume of coronary artery plaque within 18 months, compared with placebo. In the current study, alirocumab reduced LDL-C levels by 54% from baseline to 12 months. Alirocumab may therefore have had similar effects in ODYSSEY OUTCOMES in preventing plaque progression or promoting plaque regression, resulting in greater capacity for myocardial oxygen delivery and consequently a lower risk of Type 2 MI. It is not known whether PCSK9 inhibitors have favourable effects on coronary endothelial or microvascular function. The incidence of Type 2 MI as a proportion of total MIs has varied from around 1.6% to 29.6% in randomized trials and population studies. 11 Here, the incidence was in the higher portion of that range. In this trial, potent lipid-lowering with alirocumab reduced the occurrence of Type 2 MI. To our knowledge, this is the first such observation and contrasts with the lack of effect on Type 2 MI seen in the FOURIER trial. 5 The reason for this contrast is unknown, but could be related to differences in patient populations, number of events, duration of follow-up, definitions, and adjudication processes. Specifically, the ODYSSEY OUTCOMES trial included high-risk patients with recent ACS rather than stable patients with a history of MI, stroke, or peripheral vascular disease, and they were followed for longer (2.8 vs 2.2 years in the FOURIER trial the studies in the effects of treatment with a PSCK9 inhibitor on specific types of MI might also be related to differences in prevailing biomarker assays, and cut-off values. Some reports ascertaining the incidence of Type 2 MI have used specific defined oxygen supply/demand mismatch criteria, 11, 12 whereas others have used more liberal criteria. 13 The ischaemic thresholds for myocardial oxygen supply/demand imbalance vary markedly in respect to the magnitude of the stressor and the amount of underlying CAD. 14 Some of the patients in the present study with STEMI and Type 2 MI may have had plaque rupture with thrombus formation or embolization of thrombus, which may have been missed on angiography because of the low sensitivity for detecting thrombus, including beyond the plaque rupture in the proximal epicardial coronary vessel. Also, some of these patients may have had coronary artery spasm causing transmural ischaemia and STEMI.
The short-and long-term mortality rates for patients with Type 2 MI are generally higher than for Type 1 MI patients in most studies, due to an increased prevalence of comorbid conditions. [11] [12] [13] [15] [16] [17] [18] [19] [20] However, adjusted mortality may be similar. 13 Here, we found allcause death to be more than twice as high after Type 2 than Type 1 MI. The presence of significant CAD is a common finding in patients with Type 2 MI selected to undergo coronary angiography. The incidence of CAD depends on the population and how intensively they are studied. The presence of CAD in Type 2 MI ranges from 55% to 68%. 13, 21, 22 In general, patients with Type 2 MI and CAD have a worse prognosis than those without CAD. 18, 20, 22 As patients in the present study all had a recent ACS (within the past 1-12 months), it is likely that most had significant CAD and many would have benefited from lipid-lowering therapy through a decrease in plaque lipid content, and inflammatory cells perhaps leading to improved plaque stability and decreased progression of atherosclerosis. There are no data that statins or PCSK9 inhibitors modulate the risk associated with erosions. It is possible that Alirocumab by reducing LDL-C could improve coronary endothelial function. 23 In the FOURIER trial, evolocumab reduced Type 4 MI (n = 194). 5 However, in this trial we found no effect of alirocumab on reducing Type 4 MI despite a similar number of events (n = 225) as in the FOURIER trial. Several small trials have suggested that statin loading before PCI may reduce the occurrence of Type 4 MI. 24 However, the recent large randomized SECURE-PCI trial showed that two loading doses of 80 mg atorvastatin before and 24 h after a planned PCI had no effect on a composite of death, MI, stroke, or unplanned coronary revascularization. 25 Our observations are consistent with the latter trial with no apparent effect of alirocumab on reducing Type 4a, 4b, or 4c MI, with 109 events occurring with alirocumab and 116 with placebo. We pre-specified five geographic regions for the 57 participating countries (Supplementary material online, Table S8 ). Regional analysis showed that Type 2 MIs were relatively more frequent in North America (ratio of Type 2 to Type 1 MI 0.35) than in South America, Asia, and the rest of the world (ratio of Type 2 to Type 1 MI 0.16, 0.24, and 0.20, respectively). These findings could reflect regional differences in patient baseline characteristics or prevailing practice patterns influencing the ascertainment of electrocardiographic, biomarker or echocardiographic data to support MI diagnosis.
The prevalent use of therapies well-established to reduce the risk of recurrent MI were examined according to type of MI. Beta-blocker use at randomization was high and similar in patients who subsequently had Type 1 or Type 2 MI (86.5% vs. 85.1%, respectively). Large majorities of the patients with either Type 1 or Type 2 MI were treated with aspirin (94.5% and 89.3%, respectively).
Limitations
We did not specify study-specific adjudication algorithms to distinguish Type 1 and 2 MI. The trial did not mandate routine biomarker measurements following PCI or CABG to detect Type 4 and Type 5 MIs, and consequently there may have been under ascertainment of those events. The absence of any alirocumab treatment effect on the occurrence of Type 4 MI could represent Type 2 error, due to the relatively small number of these events. Classification of MI according to the development of Q-waves may have been limited because the protocol did not specify ECGs at fixed times in the study and there was no core ECG laboratory. We had no protocol-specified measurement of left ventricular function to ascertain the size of the MIs in addition to biomarker assessment. Finally, as pre-specified, we focused on first MI after randomization rather than analysing total MI events. 9 
Conclusion
In patients with ACS, alirocumab added to intensive statin therapy during 2.8 years of follow-up reduced the occurrence of both Type 1 and Type 2 MI. For Type 1 MIs, treatment benefit appeared to increase over time. The data indicate for the first time that a lipidlowering therapy can attenuate the risk of Type 2 MI. Therefore, LDL-C lowering with alirocumab below levels achieved with statins may be an important preventive treatment for both Type 1 and Type 2 MI following ACS.
Supplementary material
Supplementary material is available at European Heart Journal online. 
